Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
Notice regarding the Completion of the Pay-in Procedures for New Shares Issuance as post-delivery restricted-stock-based remuneration
Modalis to Present Preclinical Data on MDL-202 using CRISPR-GNDM epigenome editing technology at ASGCT 28th Annual Meeting
Modalis to Present MDL-202, a gene therapy for Myotonic Dystrophy Type 1 (DM1) using CRISPR-GNDM epigenome editing technology at 2025 MDF Conference
Notice Regarding Determination of Terms and Conditions of Stock Options (Share Acquisition Rights)
Notice regarding the issuance of new shares as post-issuance stock-based compensation
Notice Regarding Issuance of Stock Options (Share Acquisition Rights)
Business Plans and Matters Related to High Growth Potential
Notice regarding changes in certified public accountants
Notice regarding partial amendment of the Articles of Incorporation
Announcement on Reduction in Amounts of Stated Capital and Capital Reserves and Appropriation of Other Capital Surplus
2024 Fiscal Year End Business and Financial report
Notice Regarding the Variance between consolidated results and results of the previous year, non-consolidated results and results of the previous year
Notice Regarding the Recording of Non-Operating Income (Foreign Exchange Income)
Consolidated Financial Results for the Fiscal Year Ended December 31, 2024 [Japanese GAAP]
Modalis Therapeutics, Last Fiscal Year's Net Income Loss Narrows, Current period performance is undisclosed.
LAMA2-CMD Patent Granted in Japan
JCR Pharmaceuticals and Modalis Therapeutics Announce Transition to the Next Phase of Joint Research Agreement for Development of Novel Gene Therapy
Notice Regarding the Occurrence of an Incident of Electronic Fraud at a Subsidiary and the Recording of an Extraordinary Loss
Modalis Therapeutics Corporation, January-September (Third Quarter Cumulative) Net Income Loss Narrows, July-September Net Income Loss Narrows
Notice Regarding the Recording of Non-Operating Income (Foreign Exchange Income)